Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when OPK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOPKO Health reports Q2 2026 revenue of $163.5M, narrows operating loss to $7.0M
Filed July 27, 2026 · Period ending July 27, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 revenue rose to $163.5M from $156.8M year-over-year, driven by $29.4M in revenue recognized from Nicoya equity received under an amended RAYALDEE license agreement for Greater China, partially offset by lower services revenue following the September 2025 oncology asset sale to Labcorp.
Exhibit 99.1 view on EDGAR → -
high
Operating loss narrowed to $7.0M from $60.0M in Q2 2025; net loss improved to $8.4M ($0.01 per share) from $148.4M ($0.19 per share) in the prior-year quarter.
Exhibit 99.1 view on EDGAR → -
high
Amended Nicoya agreement grants OPKO a 15% equity stake in exchange for revised royalty and transfer pricing terms, with an initial tranche of Series A-2 Preferred Shares received and a second tranche expected in Q3 2026; the deal expands RAYALDEE's field of use in Greater China while maintaining up to $115M in milestone payments.
Exhibit 99.1 view on EDGAR → -
medium
Initiated three Phase 1 trials: MDX2003 for B-cell lymphoma, MDX2301 for COVID-19 prevention (enrollment expected to complete Q3 2026), and OPK-88006 for metabolic dysfunction-associated steatohepatitis.
Exhibit 99.1 view on EDGAR → -
high
Guided Q3 2026 revenue to $131M-$142M and full-year 2026 revenue to $560M-$585M.
Exhibit 99.1 view on EDGAR →
Summary
OPKO Health reported Q2 2026 results showing revenue growth and significant improvement in operating performance. Revenue increased 4% year-over-year to $163.5 million, with the Nicoya agreement amendment contributing $29.4 million in recognized equity value.
Operating loss narrowed sharply to $7.0 million from $60.0 million in the prior-year quarter, reflecting both the revenue mix shift and improved cost structure following the 2025 oncology asset divestiture.
The amended Nicoya partnership restructures OPKO's RAYALDEE commercialization strategy in Greater China, converting a portion of future economics into immediate equity ownership while expanding the product's field of use. The 15% stake provides direct exposure to Nicoya's commercial execution, with a second equity tranche expected in Q3 2026. The company maintains eligibility for up to $115 million in development, regulatory, and sales milestones. OPKO advanced its clinical pipeline with three Phase 1 trial initiations during the quarter, spanning oncology (MDX2003 tetraspecific T-cell engager for B-cell lymphoma), infectious disease (MDX2301 COVID-19 prevention antibody), and metabolic disorders (OPK-88006 dual GLP-1/Glucagon agonist for MASH). The company guided full-year 2026 revenue to $560-$585 million, implying second-half revenue of $396.5-$421.5 million against first-half results.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
OPKO Health disclosed Q2 2026 operating and financial highlights via press release and announced a conference call to discuss results and guidance.
Added in current filing · verify on EDGAR →
On July 27, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended June 30, 2026.
OPKO Health disclosed operating and financial highlights for the second quarter ended June 30, 2026 through a press release. The 8-K does not include the actual financial figures in the body text; those details are contained in the attached Exhibit 99.1 press release.
Added in current filing · verify on EDGAR →
The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the second quarter ended June 30, 2026, as well as provide financial guidance.
The company announced it will host a conference call to discuss Q2 2026 financial and operating results and provide financial guidance. Access details are in the attached press release.
Event · Exhibit 99.1
OPKO Health reported Q2 2026 results with revenue of $163.5M, narrowed operating loss to $7.0M, and advanced multiple clinical programs.
Added in current filing · view on EDGAR →
Consolidated total revenues for the second quarter of 2026 were $163.5 million compared with $156.8 million for the 2025 period, with the increase principally resulting from higher revenue from the transfer of intellectual property and other, partially offset by lower revenue from services following the September 2025 sale of our oncology assets to Labcorp. Operating loss for the second quarter of 2026 improved to $7.0 million compared with operating loss of $60.0 million for the corresponding 2025 quarter. Net loss for the second quarter of 2026 was $8.4 million, or $0.01 per share, compared with net loss of $148.4 million, or $0.19 per share, for the corresponding 2025 quarter.
OPKO reported Q2 2026 revenue of $163.5 million, up from $156.8 million in Q2 2025, driven by higher intellectual property revenue partially offset by lower services revenue following the September 2025 oncology asset sale to Labcorp. Operating loss narrowed significantly to $7.0 million from $60.0 million, and net loss improved to $8.4 million ($0.01 per share) from $148.4 million ($0.19 per share) in the prior-year quarter.
Added in current filing · view on EDGAR →
Revenue from the transfer of intellectual property and other rose to $46.1 million, up from $15 million in 2025, primarily driven by $29.4 million in revenue recognized from shares received in connection with an amendment to our license agreement with Nicoya who is beginning to commercialize Rayaldee in China.
OPKO recognized $29.4 million in revenue from shares received under the amended Nicoya license agreement in Q2 2026, contributing to the increase in intellectual property and other revenue to $46.1 million from $15 million in the prior-year quarter.
Added in current filing · view on EDGAR → · paraphrased
For the three months ended September 30, 2026 Low High ... Total revenue 131 142 ... For the year ended December 31, 2026 Low High ... Total revenue 560 585
OPKO provided financial guidance for Q3 2026 with total revenue expected between $131 million and $142 million, and full-year 2026 revenue guidance of $560 million to $585 million. The guidance includes services revenue of $296-$306 million, product revenue of $164-$174 million, and IP and other revenue of $100-$105 million for the full year.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 28, 2026 · How we verify